converted into a set of digital parameters using aperiodic analysis, and CSF dynamics were determined using ventriculocisternal perfusion. Propofol (3.8 ? 1.3 mg/kg) stopped epileptiform activity, as did midazolam (2.0 -+ 1.7 mg/kg). The rates of CSF formation or reabsorption and resistances to CSF reabsorption or flow at the arachnoid villi did not differ among conditions or between groups. Our results indicate that propofol and midazolam both terminate epileptiform activity without changing CSF dynamics. Implications: Propofol may be an alternative to benzodiazepines for treating lidocaine-induced epileptiform electroencephalogram activity in patients.
( there are no controlled, laboratory studies that examine the effectiveness of propofol administered after the onset of LIEEA. One aim of the present study was to determine whether posttreatment with propofol is effective, using a rabbit model of LIEEA. Midazolam was examined as a comparison treatment to propofol.
A second aim of the present study was to determine whether cerebrospinal fluid (CSF) formation rate (V,) or resistance to reabsorption of CSF (R,) are significantly altered during LIEEA, and, if so, whether either returns to baseline when LIEEA is treated with propofol or midazolam. LIEEA is accompanied by increased cerebral blood flow (CBF) and catecholamine concentrations in blood (5). Increased catecholamines decrease V,, whereas increased choroid plexus blood flow increases V, (6). The IV administration of lidoCaine in doses of lidocaine smaller than those necessary to produce LIEEA (0.5, 1.5, and 4.5 mg/kg) caused a dose-related decrease of V, and no significant change in R, in rabbits (7).
2.8-3.5 kg were anesthetized by mask induction with halothane (gradually increased from 0.5% to 3.5%, inspired) and N,O (50%, inspired) in 0,. A tracheostomy was performed, and a 3-to 4-mm endotracheal tube was inserted 1.5-2.0 cm into the trachea. Ventilation was controlled with a small animal respirator (Harvard Apparatus, Dover, MA). Ventilation was adjusted to maintain Pace, at 32 + 5 mm Hg. Thereafter, PETCO~ was continuously measured via a Datex model AS/3 monitor (Instrumentarium Corp., Helsinki, Finland), and ventilation was regulated to maintain PETCO~ at normocapnia. Rabbits were then surgically prepared for determination of mean arterial blood pressure (MAP) and blood sampling (femoral artery catheter), IV infusion (femoral vein and ear vein catheters), ventriculocisternal perfusion (needle in lateral ventricle, catheter in cisterna magna, and rate of infusion of mock CSF of 58-60 pL/min), and EEG monitoring (gold cup electrodes) as previously described (7-10). In addition, a 24-gauge catheter was inserted into the superior sagittal sinus through a burr hole located on the sagittal suture 15 mm anterior to the coronal suture to continuously measure sagittal sinus pressure (SSP). Continuous monitoring of MAP began immediately after insertion of the femoral artery catheter. The femoral vein and ear vein catheters were inserted after the femoral artery catheter and after commencement of continuous MAP monitoring. Pancuronium 0.5 mg/h was given IV through one of the venous catheters for muscle relaxation. Continuous monitoring of the EEG began only after the conclusion of the tracheostomy and insertion of the arterial, venous, and superior sagittal sinus catheters to prevent any possibility that electrocautery might damage the EEG monitor (Lifescan Brain Activity Monitor System; Diateck Medical Technology, San Diego, CA). The same concentrations of halothane and N,O in 0, used to provide anesthesia for tracheostomy and surgical exposure of the femoral vessels (i.e., before the use of a muscle relaxant) were continued after initiating the IV infusion of pancuronium and throughout the ensuing period of determining the following values for the preexperimental period: MAP, heart rate, rectal temperature, inspired and expired gas tensions, arterial blood gas tensions, CSF osmolality, EEG activity, SSP, CSF pressure, and the concentration of blue dextran 2000 (3 mg/mL; Pharmacia Fine Chemicals AB, Uppsala, Sweden) in the outflow limb of the ventriculocisternal perfusion system.
A 22-gauge, 1.5-in., short-beveled needle was placed into the left lateral cerebral ventricle through a burr hole located 5 mm posterior to the coronal suture and 5 mm lateral to the sagittal suture. An l&gauge, 2-in. catheter was directed through the atlantooccipital membrane and into the cisterna magna. Entrance into the cisterna magna was confirmed by the appearance of CSF in the catheter. A 200-PL sample of CSF was withdrawn through the cisternal catheter. The osmolality of the CSF was measured using a Wescor Model 5100 B Vapor Pressure Osmometer (Wescor, Inc., Logan, UT). Mock CSF of matching osmolality was prepared by mixing standard solutions (290,300, and 310 mOsm/kg) labeled with blue dextran 2000. Mock CSF was bubbled with 5% CO, in oxygen to adjust the pH of the solution to 7.3. The rate of infusion of mock CSF into the ventricle was controlled by using a variablespeed syringe pump and gradually increased to 58-60 FL/min while ventricular and cisternal CSF pressures were continuously monitored. Equilibration of the tracer was assessed after 1 h of ventriculocisternal perfusion. Concentrations of blue dextran in cisternal outflow samples were determined intermittently using light absorbance at 620 nm on a Beckman DU-50 Spectrophotometer (Beckman Instruments, Inc., Irvine, CA). Equilibration of the tracer was considered complete when measured blue dextran concentrations in three consecutive samples of cisternal outflow (4-6 min per sample) agreed within 2%.
After these preexperimental values had been recorded, fentanyl was given IV as an initial dose of 16 pg/kg IV over 10 min, and then as an IV infusion at 0.18 pg * kg-r * mini', and was continued until the end of the study. This dose of fentanyl was selected because it is reported to cause no significant change in CSF dynamics when administered concomitantly with halothane (0.2%, expired) and N,O in 0, (8). After the initial dose of fentanyl had been delivered and the continuous infusion of fentanyl at the lower rate begun, halothane was discontinued, and the expired concentration of halothane and the EEG were carefully and continuously monitored as the tracer in the ventriculocisternal perfusion solution equilibrated. At the first sign of the slightest change in the EEG toward higher frequency activity, the expired concentration of halothane was noted (critical concentration), and halothane was reintroduced into the inspired gas mixture to maintain the expired concentration of halothane just above the critical concentration. We chose to maintain anesthesia with fentanyllhalothanel N,O/O, (with halothane just above the critical concentration) rather than to maintain anesthesia with halothane/N,O/O, (with halothane at higher concentrations) because a high concentration of halothane may have prevented LIEEA during the subsequent experimental period. Continuous monitoring of MAP and the EEG during halothane/N,O/O, (with halothane at high concentrations) and during fentanyll halothane/N,O/O, helped to ensure that anesthesia was adequate during the latter condition.
The experimental period began once tracer equilibration was complete. Twelve rabbits were examined at four experimental conditions: (A) baseline, (B) LIEEA, (C) treatment with midazolam or propofol, and (D) return to baseline (discontinuation of lidoCaine and midazolam or propofol). Rabbits were randomly assigned for Condition C so that six received midazolam (midazolam group) and six received propofol (propofol group). At the beginning of Condition B, lidocaine was given IV continuously at 5 mg * kg-' * mini until the onset of LIEEA. Thereafter, lidocaine was continued at l-3 mg * kg-* * rnin~l as needed to maintain LIEEA throughout Condition B. The same lidocaine infusion rate was continued until the end of Condition C. At the beginning of Condition C, repeated 1.25-mg doses of midazolam (midazolam group) or 2.5-mg doses of propofol (propofol group) were given IV until suppression of LIEEA. Thereafter, midazolam or propofol was continuously infused IV at rates necessary to maintain drug-induced suppression of LIEEA.
The use of six rabbits per group was based on the standard equation relating sample size to variance, power, significance level (two-sided test), and difference between null and alternative means (11). The variance value used in the calculation was the mean of values reported in the three studies from our laboratory that used the present ventriculocisternal perfusion technique, 0.24 (i.e., expressed as a ratio of the average mean value) (7,12,13). The difference value used in the calculation was the smallest difference found to be significant in the same three previous studies, 0.27 (expressed as a ratio of the same average mean value used for the variance calculation).
The power value used in the calculation was 0.8 and the significant level was 0.05.
At the beginning of Condition B, halothane was discontinued, and the expired concentration of halothane was monitored.
With the very low fresh gas flow we used, the discontinuation of halothane caused a modest decrease in the expired concentration of halothane. The modest decrease in halothane was intended to compensate for the increase in total anesthetic depth that otherwise would have ensued when large doses of lidocaine were combined with fentanyl/halothane/N,0/0,.
During Condition D, halothane was reintroduced into the inspired gas mixture as indicated by the EEG to compensate for the decreased contribution of lidocaine and midazolam or propofol to total anesthetic depth. Arterial blood samples (2 mL) were obtained for determination of plasma lidocaine concentrations at the end of Conditions B and C. Plasma samples were stored at -20°C until analysis, at which time the lidocaine concentration was measured by gas chromatography with nitrogenphosphorus detection. V,, the rate of reabsorption of CSF (V,), R,, resistance to CSF flow at arachnoid villi (R,,), and systemic values were determined at each experimental condition. V,, V,, and R, were calculated as previously described (7-10,14,15). R,, was calculated as driving pressure (the pressure decrease across the arachnoid villi, i.e., the difference between ventricular CSF pressure and SSP) divided by V,. R,, was calculated so that it could be compared with R,. R,,, as described by Johnston (16), offers an attractive alternative to R, because it requires the study of experimental subjects at only one CSF pressure state, rather than at two or more CSF pressure states, as is the case for calculation of R,.
Statistical comparisons of parametric data were made within the two drug groups using repeatedmeasures analysis of variance (ANOVA), and between groups using two-way repeated-measures ANOVA (Sigma Stat; Jandel Scientific, San Rafael, CA). ANOVA was performed using one between-group factor of drug type nested within each rabbit. Post hoc comparisons of experimental conditions were made using Dunnett's test. For all data analyses, P < 0.05 was considered significant. Values are tabulated as mean ? so.
Results
Baseline EEG values were not significantly different between the midazolam and propofol groups. Combined mean values were power of 15.9 +-12.0, 12.2 t 13.8, 3.8 + 4.2, and 2.2 -+ 1.8 pV2 * lo3 * rnin~l and number of waveforms of 67 ? 15, 100 ? 45, 85 ? 45, and 120 2 113 mini for the standard frequency bins of 6 (0.5-3.0 Hz), 8 (3.1-8.0 Hz), cy. (8.1-12.0 Hz), and /3 (12.1-29.9 Hz), respectively.
Total power was 33.8 ? 25.3 ~~~ * lo3 * mine1 and the activity edge was 12 ? 5 Hz. With the onset of LIEEA, 0, cx, p, and total power increased, and the number of 6 and 8 waveforms decreased significantly in both groups (Figures 1 and  2) . The plasma lidocaine concentration in the midazolam group, 30.9 t 12.5 Fg/kg, was not significantly different from that in the propofol group, 41.0 + 9.6 pgkg.
Both midazolam and propofol terminated LIEEA despite a continued IV infusion of lidocaine. The mean dose of midazolam was 2.0 % 1.7 mg/kg, and that of propofol was 3.8 ? 1.3 mg/kg. EEG values after treatment with midazolam or propofol were not significantly different from baseline. The subsequent infusion rates necessary to maintain dru -induced is ~ suppression of LIEEA were 0.5 mg * kg-* h * of midazolam and 12 mg * kg 1 * h-i of propofol. are presented in Table 2 . CSF values for each experimental condition are presented in Table 3 .
Discussion
One principal finding of this study is that posttreatment with propofol terminated LIEEA. This finding is consistent with the single case reported by Bishop and Johnstone (4), in which posttreatment with propofol abolished lidocaine-induced seizures during carotid endarterectomy. Consistent with our results, propofol is reported to exhibit anticonvulsant activity against seizures induced by bicuculline, kainic acid, and N-methyl-o-aspartic acid in mice (17), to be as effective as thiopental against seizures induced by phenylenetetrazol and electroshock in mice (18), and to increase the threshold for picrotoxin-induced seizures in rabbits (19). That midazolam also terminated LIEEA in this study supports the validity of our model on the basis that a treatment well recognized to oppose LIEEA (i.e., benzodiazepines) in previous studies was also effective in our model.
Our observation that the plasma lidocaine concentration was higher at the onset of LIEEA (Condition B) than during continued IV infusion of lidocaine (at the same rate) combined with IV bolus doses of midazolam or propofol (Condition C) likely reflects the pharmacokinetics of passage of lidocaine from blood into brain tissue (20). While lidocaine was first being infused (Condition B), a high concentration of lidocaine in blood was necessary to achieve adequate concentrations in brain to elicit epileptiform activity. As lidoCaine continued to be infused and the concentration of lidocaine in brain tissue equilibrated with that in blood, it was no longer necessary for the blood concentration of lidocaine to be as high as when the lidocaine infusion was first begun to achieve "epileptic" brain concentrations.
A second principal finding of this study is that LIEEA was not associated with significant changes in V,, R,, or R,,. The magnitude of decrease of V, over the duration of the study, 2 ? 2 pL/min in each group, is similar to that previously reported in rabbits undergoing ventriculocisternal perfusion during anesthesia with halothane and N,O in 0, and receiving small doses (0.5-1.5 mg/kg) of lidocaine IV (6) or cocaine IV (6), or during anesthesia with propofol, fentanyl, and N,O in 0, (9) or propofol, halothane, and N,O in 0, (9). Several factors might have been expected to significantly alter V, during LIEEA. These include effects of neuronal activation, such as increased cerebral capillary and choroid plexus blood flow and increased choroid plexus metabolic activity (which have been reported to increase VJ, increased catecholamine concentrations in blood (which have been reported to decrease V,), and effects of IV lidocaine such as depression of the cerebral metabolic rate for oxygen (CMRO,) and CBF (which have been reported to decrease V,) (6). Our finding of unchanged V, during LIEEA suggests that the CBF-and CMRO,-stimulating effects of epileptiform EEG activity offset the depressant effects of lidocaine.
Certain V, and R,, data support the validity of our model. Baseline V, values in both groups in this study are similar to those reported from this laboratory, as well as results reported by other authors (10, 15, 21, 22) . V, increased and R,, decreased significantly at each CSF pressure state 2 for each experimental condition in both the midazolam and propofol groups, consistent with previous reports that V, increases and R, decreases with increased CSF pressure (6). The absence of any significant difference in R, between experimental conditions in the midazolam and propofol groups (despite the trend toward increased R, during 
